Day: November 23, 2024

‘I can’t deal with managing them’: I juggle 18 credit cards. How do I close them without ruining my credit score?

This post was originally published on this site

Okay, talk me down. I have 18 credit cards and would like to close five of them — all at once.  

Actually, I’d like to close more, but I have five targets for now. The cards are paid in full every month. It’s been many years since I have carried a balance and I have very high limits, so charges barely make a blip on my credit-utilization ratio.

I can’t deal with managing them — the game of keeping them open and checking to make sure there are no mystery charges. I’m old but active, and I don’t want my family to have to deal with this when I go. How bad would it be to close down five at all at once?

Tired of Juggling

Related: ‘It’s so unfair!’ I’m miserable in my job. I’m 58 and have $1 million in a 401(k) and Roth IRA. Can I afford to quit?

Dear Juggler,

It’s hard to find someone who would say closing a credit card is a good idea. The chief reason is that it will hurt your credit score. But you should not be held hostage by your credit score, and 18 credit cards is at least 15 too many, so close them you shall. You can’t break up with a partner without hurting their feelings, you can’t make an omelet without breaking a few eggs, and you can’t close your credit cards without dinging your credit score. That’s life, I’m afraid.

I’m in favor of you closing five and, hopefully, more. If you have to make any big purchase like a car and you need a loan, do it now. If you already have a mortgage and you don’t intend to take out a personal loan for the next six months or so, this is a good time to rid yourself of these cards once and for all. There are card closures that should take priority, once you have made sure that there is zero balance on those cards, and you have redeemed their points.

Cancel credit cards with the lowest credit limit (the less you use of your credit limit, the better). Generally, most experts recommend keeping your credit-utilization ratio below 30%. “Canceling a card may increase your credit utilization — the proportion you use of your available credit — which can also lower your score,” Experian says. If you have an overall limit of $1,000 and you use $250 of it, your credit-utilization ratio is 25%, it says; if you use $500? It’s 50%.

Some other rules of thumb when closing credit cards: The older your credit, the better risk you are for lenders, so cancel your newest cards first. Finally, prioritize canceling cards with hefty annual fees; if you’re not using them, there’s no point in paying them. “It can be good to show lenders that you can successfully manage multiple credit accounts, as they may see this as evidence that you’re a reliable borrower,” Experian says. 

The main credit bureaus — Equifax EFX, Transunion TRU and Experian UK:EXPN — calculate their scores differently, so your score would be dinged differently depending on the bureau. For instance, a FICO FICO score has five categories: payment history (35%), amounts owed (30%), length of credit history (15%), new credit (10%) and credit mix (10%). In other words, FICO values consumers who stay on top of their finances.

Your credit score should be fully recovered a year from now, or less. Godspeed with managing your finances going forward, keeping your credit utilization low, and maintaining a long credit history. This will be crucial if you require any kind of loan over the next few years. The best time to take a hit to your credit score is, of course, when you don’t actually need it. 

You can email The Moneyist with any financial and ethical questions at qfottrell@marketwatch.com, and follow Quentin Fottrell on X, the platform formerly known as Twitter. 

The Moneyist regrets he cannot respond to letters individually.

More columns from Quentin Fottrell:

‘I never thought they would be in this situation’: Our daughter and son-in-law spend money as fast as his parents give it to them. Do we butt in?

‘We don’t have a joint account’: My husband has a tenant from hell. He forces me to pay for all his rental-property expenses. Am I being used?

I give my mother’s ailing next-door neighbor $500 a month. She agreed to sell me her house, although she’ll continue to live there. Is this wise?

Check out The Moneyist’s private Facebook group, where members help answer life’s thorniest money issues. Post your questions, or weigh in on the latest Moneyist columns.

By emailing your questions to The Moneyist or posting your dilemmas on The Moneyist Facebook group, you agree to have them published anonymously on MarketWatch.

By submitting your story to Dow Jones & Co., the publisher of MarketWatch, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

This post was originally published on this site

SAN JOSE, Calif., Nov. 22, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset.


Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

With Anixa’s strong balance sheet and excess cash, this strategic decision aims to diversify the Company’s treasury holdings while positioning Anixa to benefit from the potential long-term value of digital assets.

The Company also reaffirmed its ongoing stock buyback program as part of its commitment to enhancing shareholder value.

“We are pleased to add this asset class as an investment option for us. We are thrilled that both of our clinical trials—a breast cancer vaccine (NCT04674306), and an ovarian cancer therapy treating recurrent and resistant patients (NCT05316129)—have produced results that have exceeded our expectations. We are proud of our strategy to move our trials forward, while burning relatively low levels of cash. Our decision about Bitcoin is an additional approach to prudent financial management, enabling greater shareholder value,” said Dr. Amit Kumar, CEO of Anixa.

“As we continue to execute on our mission of advancing life-changing cancer therapies, we are also focused on creating long-term financial value for our shareholders,” said Mike Catelani, President and CFO of Anixa. “With Bitcoin‘s growing recognition as a mainstream asset class, we believe it represents a valuable addition to our treasury reserve strategy. The approval of Bitcoin ETFs and increasing participation from institutional investors highlight its rising importance in global markets. Its unique inflation-resistant qualities and potential as a reliable store of value aligns with our goal of optimizing long-term financial stability and growth. Combined with our stock buyback program, this initiative reflects our confidence in the Company’s growth trajectory and our dedication to delivering shareholder returns.”

For those interested in learning more about the Company, a 30-minute presentation given at a recent investor conference is available on the Company’s website at https://ir.anixa.com/events, or at the conference organizer’s web page here: Webinar Registration – Zoom

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-board-of-directors-approves-purchase-of-bitcoin-as-treasury-reserve-asset-302313759.html

SOURCE Anixa Biosciences, Inc.

Featured Image: depositphotos @ kentoh

Disclaimer

Compare